• Affiliate Professor, Global Health
  • Senior Investigator/Scientist, Center for Global Infectious Disease Research, Seattle Children's Research Institute

Seattle, WA 98102
United States

Phone Number: 
Select from the following:

My research is focused in two main areas: (i) understanding the pathogenic mechanisms and underlying biology of the global pathogen Mycobacterium tuberculosis; and (ii) discovering and developing novel drugs that are effective at curing drug sensitive and drug resistant tuberculosis.

Current translational work within my group encompasses a range of early stage drug discovery including drug target identification and validation, high throughput screening and medicinal chemistry. My applied research has covered a broad range of chemistry and biology as applied to drug discovery from high throughput screening through to lead optimization. My current fundamental research addresses mechanisms of antibiotic resistance, the mode of action of antibiotics and the investigation of essential cellular processes in mycobacteria. I also have an interest in gene regulation in mycobacteria and cell wall biosynthesis pathways. In addition, using M. tuberculosis as a paradigm, I seek to understand the mechanisms by which antimicrobials ultimately cause cell death.

  • PhD (National Institute For Med Res (UK))
  • BSc (University of London (UK))
Country Affiliations 
Health Topics 
  • Infectious Diseases
  • Leishmaniasis
  • Pathogenesis
  • TB
DGH Centers, Programs and Initiatives and Affiliated Organizations 

Novel MenA inhibitors are bactericidal against Mycobacterium tuberculosis and synergize with electron-transport chain inhibitors. 2019. B.J. Berube, D. Russell, L. Castro, S. Choi, P. Narayanasamy and T. Parish. Antimicrob Ag Chemother. 63:e0266-18 PMID: 30962346 doi: 10.1128/AAC.02661-18

Identification of compounds with pH-dependent bactericidal activity against Mycobacterium tuberculosis. 2019. J. Early, J. Ollinger, C. Darby, T. Alling, S. Mullen, A. Casey, B. Gold, J. Ochoada, T. Wiernicki, T. Masquelin, C. Nathan, P. Hipskind and T. Parish. ACS Inf Dis. 5: 272-280. PMCID: PMC6371205

Efficacy and improved resistance potential of a cofactor-independent InhA inhibitor of Mycobacterium tuberculosis in a C3HeB/FeJ mouse model. 2019. G. Robertson, V. Ektnitphong, M. Scherman, M. McNeil, D. Dennison, A. Korkegian, A. Smith, J. Halladay, D. Carter, Y. Xia, Y. Zhou, W. Choi, P. Berry, W. Mao, V. Hernandez, M.R.K. Alley, T. Parish, and A. Lenaerts. Antimicrob. Ag. Chemother. 63: e02071-18

The relevance of persisters in tuberculosis drug discovery. 2019. S. Mandal, S. Njikan, A. Kumar, J.V. Early and T. Parish. Microbiology.165:492-499.

Identification of morpholinothiophenes as novel Mycobacterium tuberculosis inhibitors targeting QcrB. 2018. L. Cleghorn, P. Ray, J. Odingo, A. Kumar, A. Korkegian, T. Masquelin, A. Lopez Moure, C. Wilson, S. Davis, M. Huggett, P. Turner, A. Smith, O. Epemolu, F. Zuccotto, J. Riley, P. Scullion, Y. Shishikura, L. Ferguson, J. Rullas, L. Guijarro, K. Read, S. Green, P. Hipskind, T. Parish, P. Wyatt. J Med Chem. 61: 6592-6608.

Identification of enolase as the target of 2-aminothiazoles in Mycobacterium tuberculosis. 2018. H. Wescott, E.S. Zuniga, A. Bajpai, C. Trujillo, S. Ehrt, D.S. Schnappinger, D.M. Roberts, and T. Parish. Frontiers in Microbiology. 9: 2542.

Identification of phenoxyalkylbenzimidazoles with anti-tubercular activity. 2015. N.S. Chandrasekera, T. Alling, M.A. Bailey, M. Files, J.V. Early, J. Ollinger, Y. Ovechkina, T. Masquelin, P.V. Desai, J.W. Cramer, P.A. Hipskind, J.O. Odingo, and T. Parish. J. Med Chem. 58:7273-7285.